Lung Cancer Awareness Month

Focus on Non-Small Cell Lung Cancer

Featured Content

Advent of Hybrid OR Signals Paradigm Shift in Lung Cancer Surgery

One in four cancer deaths are attributable to lung cancer, which is more than breast, prostate, and colon cancers combined, according to the American Cancer Society. One major contributor to the high mortality rate has been the challenge of diagnosing lesions in the lungs.

Read More

Lung and Mediastinum

Current Opinion in Oncology

‘Early-stage’ nonsmall cell lung cancer (NSCLC) refers to stage I and stage II disease, and selected cases of stage IIIA disease where complete tumor resection is feasible.

Read More

Advanced NSCLC: EGFR Exon 20 Targeting Success

Efficacy and safety outcome findings from the phase I/II open-label multi-center study using a drug targeting the EGFR exon 20 insertion oncogenic driver among patients with advanced non-small cell lung cancer (NSCLC) with and without brain metastases (who had previously been treated with chemotherapy) were reported at the 2019 ASCO Annual Meeting.

Read More

Free Download! NSCLC Anatomical Chart

Investigational Antibody Shows Activity in Solid Tumors With Gene Fusions

An investigational bispecific HER2/HER3 antibody leads to clinical responses in patients who harbor fusions in the gene neuregulin 1 (NRG1), including those with metastatic pancreatic ductal adenocarcinoma (PDAC) or metastatic non-small cell lung cancer (NSCLC), according to a new study.

Read More

Short-Term Mortality in Stage I NSCLC

American Journal of Clinical Oncology

Although lobectomy is the standard of care in stage I non–small cell lung cancer (NSCLC), medical comorbidities increase surgical risk in elderly patients

Read More

Loading